Dendreon Corp fka DNDNQ

[Gametheory101]

Thanks.

My quest is in really trying to ascertain how many patients maybe left in the P-11 trial who have not seen PSA progression.

The trial with Avastin was statistically significant with only 22 patients. In that trial, median PSA doubling time went from around 7 months to 12 months. We are now 16 months past the end of trial enrollment. If you count the Lupron shot and 3 month interval, we are still 13 months past then end of enrollment. Since the trial started in 2001, we don't know how many participants enrolled in the last 3 to 4 months of the trial.

Simply intrigued by the amount of time its taking P-11 to reach the first two PSA endpoints and how many participants have not yet evented.

Sorry to go on, but could you explain "the number of events and the HR that matters."